Article
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
Gene therapy - 1 Feb 2001
Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D
Abstract excerpt
Novel therapies are needed for locally advanced pancreatic carcinoma. ONYX-015 (dl1520) is an E1B-55 kDa region-deleted adenovirus that selectively replicates in and lyses tumor cells with abnormalities in p53 function (eg gene mutation). We carried out a phase I dose escalation study of ONYX-015 in patients with unresectable pancreatic cancer. ONYX-015 was administered via CT-guided injection (n = 22 patients)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.